BR112015005117A2 - métodos de tratamento da doença de alzheimer e suas composições farmacêuticas - Google Patents

métodos de tratamento da doença de alzheimer e suas composições farmacêuticas

Info

Publication number
BR112015005117A2
BR112015005117A2 BR112015005117A BR112015005117A BR112015005117A2 BR 112015005117 A2 BR112015005117 A2 BR 112015005117A2 BR 112015005117 A BR112015005117 A BR 112015005117A BR 112015005117 A BR112015005117 A BR 112015005117A BR 112015005117 A2 BR112015005117 A2 BR 112015005117A2
Authority
BR
Brazil
Prior art keywords
methods
disease
pharmaceutical compositions
treating alzheimer
enhance
Prior art date
Application number
BR112015005117A
Other languages
English (en)
Other versions
BR112015005117B1 (pt
Inventor
Schmidt Ellen
Areberg Johan
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49118521&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015005117(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of BR112015005117A2 publication Critical patent/BR112015005117A2/pt
Publication of BR112015005117B1 publication Critical patent/BR112015005117B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

1/1 resumo "métodos de tratamento da doença de alzheimer e suas composições farmacêuticas" a presente invenção descreve métodos de tratamento de demência compreendendo a administração de uma dose diária eficaz de n-(2-(6-fluoro-lhindol- 3-il)etil-(2,2,3,3-tetrafluoropropoxi)benzilamina para melhorar ou aumentar o efeito de um inibidor de acetilcolinesterase.
BR112015005117-0A 2012-09-09 2013-09-06 Usos de n-(2-(6-fluoro-1h-indol-3-il)etil)-3-(2,2,3,3-tetrafluoropropoxi) benzilamina BR112015005117B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261698664P 2012-09-09 2012-09-09
US61/698,664 2012-09-09
US201361782084P 2013-03-14 2013-03-14
US61/782,084 2013-03-14
PCT/EP2013/068516 WO2014037532A1 (en) 2012-09-09 2013-09-06 Methods of treating alzheimer's disease and pharmaceutical compositions thereof

Publications (2)

Publication Number Publication Date
BR112015005117A2 true BR112015005117A2 (pt) 2017-07-04
BR112015005117B1 BR112015005117B1 (pt) 2022-06-21

Family

ID=49118521

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015005117-0A BR112015005117B1 (pt) 2012-09-09 2013-09-06 Usos de n-(2-(6-fluoro-1h-indol-3-il)etil)-3-(2,2,3,3-tetrafluoropropoxi) benzilamina

Country Status (33)

Country Link
US (4) US9375418B2 (pt)
EP (1) EP2892563B1 (pt)
JP (2) JP6693744B2 (pt)
KR (2) KR102342127B1 (pt)
CN (1) CN104619344A (pt)
AP (1) AP2015008306A0 (pt)
AU (1) AU2013311573B2 (pt)
BR (1) BR112015005117B1 (pt)
CA (1) CA2883751C (pt)
CL (1) CL2015000578A1 (pt)
CY (1) CY1121062T1 (pt)
DK (1) DK2892563T3 (pt)
EA (1) EA030448B1 (pt)
ES (1) ES2703630T3 (pt)
GE (1) GEP201706776B (pt)
HK (1) HK1212217A1 (pt)
HR (1) HRP20182069T1 (pt)
IL (1) IL237369B (pt)
JO (1) JO3459B1 (pt)
LT (1) LT2892563T (pt)
MX (1) MX368305B (pt)
MY (1) MY182539A (pt)
NI (1) NI201500031A (pt)
NZ (1) NZ630589A (pt)
PL (1) PL2892563T3 (pt)
PT (1) PT2892563T (pt)
RS (1) RS58104B1 (pt)
RU (1) RU2675786C2 (pt)
SG (1) SG11201501774QA (pt)
SI (1) SI2892563T1 (pt)
TN (1) TN2015000076A1 (pt)
TW (1) TWI632909B (pt)
WO (1) WO2014037532A1 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0412263B1 (pt) 2003-07-22 2019-10-15 Arena Pharmaceuticals, Inc. Derivados de diaril e aril heteroaril uréia, uso e composição farmacêutica contendo os mesmos, bem como processo para preparação da dita composição
EP2254564A1 (en) 2007-12-12 2010-12-01 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
JO3459B1 (ar) 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر
US9040534B2 (en) 2013-03-14 2015-05-26 Janssen Pharmaceutica Nv [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators
JO3509B1 (ar) 2013-03-14 2020-07-05 Janssen Pharmaceutica Nv معدلات p2x7
JO3773B1 (ar) 2013-03-14 2021-01-31 Janssen Pharmaceutica Nv معدلات p2x7
TW201522307A (zh) 2013-03-14 2015-06-16 百靈佳殷格翰國際股份有限公司 經取代２－氮雜－雙環［２．２．１］庚烷－３－羧酸（苄基－氰基－甲基）－醯胺組織蛋白酶ｃ抑制劑
US9096596B2 (en) 2013-03-14 2015-08-04 Janssen Pharmaceutica Nv P2X7 modulators
JO3639B1 (ar) * 2014-07-04 2020-08-27 H Lundbeck As صورة متعددة الشكل جديدة لـ n-[2-(6-فلورو-1h-إندول-3-يل)إيثيل]-3-(2،2،3،3-تترا فلورو بروبوكسي)بنزيل أمين هيدروكلوريد
JP6592510B2 (ja) 2014-09-12 2019-10-16 ヤンセン ファーマシューティカ エヌ．ベー． Ｐ２ｘ７調節因子
SI3191487T1 (sl) 2014-09-12 2019-12-31 Boehringer Ingelheim International Gmbh Spirociklični inhibitorji katepsina C
CN105175307A (zh) * 2014-11-18 2015-12-23 苏州晶云药物科技有限公司 Lu AE58054的盐酸盐晶型A及其制备方法和用途
US20160324852A1 (en) * 2015-05-07 2016-11-10 Axovant Sciences Ltd. Compositions and methods of treating a neurodegenerative disease
RU2017145976A (ru) 2015-06-12 2019-07-15 Аксовант Сайенсиз Гмбх Производные диарил- и арилгетероарилмочевины, применимые для профилактики и лечения нарушения поведения во время REM-фазы сна
KR20180064373A (ko) 2015-07-15 2018-06-14 엑소반트 사이언시즈 게엠베하 신경퇴행성 질환과 관련된 환각의 예방 및 치료에 유용한 5-ht2a 세로토닌 수용체의 조절자로서의 다이아릴 및 아릴헤테로아릴 우레아 유도체
AU2017256623B2 (en) * 2016-04-26 2022-07-21 H. Lundbeck A/S Use of an acetylcholinesterase inhibitor and idalopirdine for reducing falls in Parkinson's disease patients
US10864191B2 (en) * 2016-05-11 2020-12-15 H. Lundbeck A/S 5-HT6 receptor antagonists for use in the treatment of Alzheimer's disease with apathy as comorbidity
SG11201809856SA (en) 2016-05-18 2018-12-28 Suven Life Sciences Ltd Combination of pure 5-ht6 receptor antagonists with acetylcholinesterase inhibitors
CN106309436A (zh) * 2016-07-25 2017-01-11 宁波大学 可用作乙酰胆碱酯酶抑制剂的色胺衍生物及其用途
CN107118146B (zh) * 2017-04-13 2019-09-03 宁波大学 一种6-溴色胺衍生物及其制备方法和用途
SI3630098T1 (sl) * 2017-05-24 2021-07-30 H. Lundbeck A/S Kombinacija antagonista receptorja 5-HT6 in zaviralca acetilholinesteraze za uporabo pri zdravljenju Alzheimerjeve bolezni pri podpulaciji pacientov, ki nosijo alele ApoE4
US20200102311A1 (en) 2018-09-28 2020-04-02 Janssen Pharmaceutica Nv Monoacylglycerol Lipase Modulators
EP3856178A1 (en) 2018-09-28 2021-08-04 Janssen Pharmaceutica NV Monoacylglycerol lipase modulators
EP4038070A1 (en) 2019-09-30 2022-08-10 Janssen Pharmaceutica NV Radiolabelled mgl pet ligands
NL2024431B1 (en) 2019-12-11 2021-09-07 Sulfateq Bv Compounds for treatment of alzheimer’s disease
KR20220157999A (ko) 2020-03-26 2022-11-29 얀센 파마슈티카 엔.브이. 모노아실글리세롤 리파아제 조절제

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3597149A (en) 1969-04-29 1971-08-03 Showa Denko Kk Inhibition of gas-fume fading of dyed cellulose acetate material
FR2181559A1 (en) 1972-04-28 1973-12-07 Aec Chimie Organique Bio N-Phenylalkyl-N-3-indolylalkyl-alkylamines - with sedative, neuroleptic, analgesic, hypotensive, antiserotonin, adrenolytic activity
JPS5764632A (en) 1980-10-09 1982-04-19 Mitsui Toatsu Chem Inc Novel 2-arylethyl ether derivative and thioether derivative, their production and insecticide and acaricide
US5202336A (en) 1986-09-24 1993-04-13 Bayer Aktiengesellschaft Antiflammatory quinolin methoxy phenylsulphonamides
DE3632329A1 (de) 1986-09-24 1988-03-31 Bayer Ag Substituierte phenylsulfonamide
SE9103745D0 (sv) 1991-12-18 1991-12-18 Wikstroem Haakan Aryl-triflates and related compounds
CA2147991A1 (en) 1993-09-01 1995-03-09 Richard A. Glennon Tryptamine analogs with 5-ht1d selectivity
US5504101A (en) 1994-05-06 1996-04-02 Allelix Biopharmaceuticals, Inc. 5-HT-1D receptor ligands
PT1032559E (pt) 1997-09-29 2007-02-28 Aventis Pharma Inc Derivados de aminoalquilfenol para tratamento de depressão e disfunção da memória
GB9820113D0 (en) 1998-09-15 1998-11-11 Merck Sharp & Dohme Therapeutic agents
DE69930308T2 (de) 1998-12-11 2006-11-30 Virginia Commonwealth University Selektive 5-ht 6-rezeptor-liganden
CN1344270A (zh) 1999-01-13 2002-04-10 千年药品公司 作为趋化因子受体调节剂的官能化杂环
US6750348B1 (en) 1999-03-24 2004-06-15 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
HU230322B1 (hu) * 2001-03-29 2016-01-28 Eli Lilly And Co. N-(2-Aril-etil)-benzil-amin 5-HT6 receptor antagonisták és az ezeket tartalmazó gyógyszerkészítmények
RU2252936C2 (ru) 2002-12-05 2005-05-27 Институт физиологически активных веществ РАН S-замещенные n-1-[(гетеро)арил]алкил-n`-[(гетеро)арил]алкилизотиомочевины, способ их получения, фармацевтическая композиция, способ изучения глутаматэргической системы, способы лечения (варианты)
PE20071143A1 (es) 2006-01-13 2008-01-20 Wyeth Corp Composicion farmaceutica que comprende un inhibidor de acetilcolinesterasa y un antagonista 5-hidroxitriptamina-6
ATE509636T1 (de) 2006-06-23 2011-06-15 Esteve Labor Dr Kombination aus einem cholinesterase-hemmer und einer verbindung mit 5-ht6-rezeptor-affinität
AR061637A1 (es) 2006-06-26 2008-09-10 Epix Delaware Inc Composiciones y metodos de tratamiento de trastornos del snc
JP2013500268A (ja) * 2009-07-23 2013-01-07 シャイア エルエルシー ガランタミンアミノ酸およびペプチドプロドラッグならびにその使用
TW201139370A (en) 2009-12-23 2011-11-16 Lundbeck & Co As H Processes for the manufacture of a pharmaceutically active agent
JO3459B1 (ar) 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر

Also Published As

Publication number Publication date
CN104619344A (zh) 2015-05-13
SI2892563T1 (sl) 2019-02-28
TWI632909B (zh) 2018-08-21
AU2013311573B2 (en) 2017-10-12
KR20150065680A (ko) 2015-06-15
RU2015107877A (ru) 2016-10-27
RS58104B1 (sr) 2019-02-28
CA2883751A1 (en) 2014-03-13
EP2892563A1 (en) 2015-07-15
HK1212217A1 (en) 2016-06-10
WO2014037532A1 (en) 2014-03-13
KR20200137028A (ko) 2020-12-08
CL2015000578A1 (es) 2015-05-15
TW201414474A (zh) 2014-04-16
HRP20182069T1 (hr) 2019-02-08
IL237369A0 (en) 2015-04-30
RU2675786C2 (ru) 2018-12-25
CY1121062T1 (el) 2019-12-11
JO3459B1 (ar) 2020-07-05
ES2703630T3 (es) 2019-03-11
SG11201501774QA (en) 2015-05-28
PL2892563T3 (pl) 2019-04-30
EP2892563B1 (en) 2018-11-14
US20140073681A1 (en) 2014-03-13
PT2892563T (pt) 2019-01-10
DK2892563T3 (en) 2019-01-21
CA2883751C (en) 2020-11-24
MY182539A (en) 2021-01-25
US9375418B2 (en) 2016-06-28
AU2013311573A8 (en) 2015-03-19
IL237369B (en) 2018-11-29
US20160354343A1 (en) 2016-12-08
NZ630589A (en) 2015-12-24
BR112015005117B1 (pt) 2022-06-21
KR102342127B1 (ko) 2021-12-21
TN2015000076A1 (en) 2016-06-29
EA030448B1 (ru) 2018-08-31
NI201500031A (es) 2016-02-15
US9687473B2 (en) 2017-06-27
AP2015008306A0 (en) 2015-03-31
US20160256437A1 (en) 2016-09-08
GEP201706776B (en) 2017-11-27
JP2019059760A (ja) 2019-04-18
MX368305B (es) 2019-09-27
LT2892563T (lt) 2019-01-10
US10660878B2 (en) 2020-05-26
US20180071254A1 (en) 2018-03-15
MX2015002879A (es) 2015-07-06
EA201590353A1 (ru) 2016-03-31
JP6693744B2 (ja) 2020-05-13
US9789085B2 (en) 2017-10-17
AU2013311573A1 (en) 2015-03-12
JP2015528471A (ja) 2015-09-28

Similar Documents

Publication Publication Date Title
BR112015005117A2 (pt) métodos de tratamento da doença de alzheimer e suas composições farmacêuticas
PH12017501306A1 (en) Inhibitors of histone demethylases
PH12017500725A1 (en) Indole carboxamide compounds useful as kinase inhibitors
BR112017009647A2 (pt) 2-amino-3,5-difluoro-3,6-dimetil-6-fenil-3,4,5,6-tetraidropiridinas como inibidoras da bace1 para tratar a doença de alzheimer
BR112017003658A2 (pt) composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica.
PH12016501600A1 (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
MX2015008957A (es) Fluoro-[1,3]oxazinas como inhibidores de beta-secretasa 1 (bace1).
IN2015DN00376A (pt)
EA201300471A1 (ru) Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3
UA113538C2 (xx) Фторметил-5,6-дигідро-4h-$1,3]оксазини
PH12015502365A1 (en) Bace1 inhibitors
BR112014019399A2 (pt) métodos de tratamento da fibrose
PH12014502623A1 (en) Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors
EA201790315A1 (ru) Модуляторы x-рецепторов печени
PH12017501668A1 (en) Bace1 inhibitors
MX2016008968A (es) Compuestos organicos.
BR112015007095A8 (pt) derivados de di-hidro-6-azafenaleno para o tratamento de doenças do snc, oncológicas e distúrbios relacionados, composição farmacêutica compreendendoos e uso dos referidos derivados
MX2016016061A (es) 2,2,2-trifluoroetil-tiadiazinas.
EA201401142A1 (ru) Замещенные 6-аминоникотинамиды, несущие он-содержащую группу, в качестве модуляторов kcnq2/3
MA37957A1 (fr) Procédés de traitement de la maladie d'alzheimer et compositions pharmaceutiques associées
SA515360233B1 (ar) مثبطات إنزيمات هستون ديميثيلاز
BR112015028884A2 (pt) tratamento ou prevenção de depressão utilizando mentol e/ou icilina
TH167631B (th) วิธีการบำบัดโรคอัลไซเมอร์และองค์ประกอบทางเภสัชกรรมของมัน
BR112013005873A2 (pt) composto, composição farmacêutica e método de tratamento da dor

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/09/2013, OBSERVADAS AS CONDICOES LEGAIS